Clinical Trials Directory

Trials / Unknown

UnknownNCT01711697

An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
16 (actual)
Sponsor
Emory University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This phase I trial studies the best dose of radiation therapy in treating patients with locally advanced non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy, such as stereotactic body radiation therapy (SBRT), that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. SBRT has been shown to provide excellent results when used in early stage lung cancer, but has not yet been applied to patients with more advanced disease.

Detailed description

PRIMARY OBJECTIVE: To test the safety and tolerability of an alternative fractionation regimen in locally advanced non-small cell lung cancer (NSCLC), consisting of 44 Gy with concurrent chemotherapy followed by a stereotactic body radiation therapy (SBRT) boost to remaining parenchymal and nodal disease. The maximum tolerated dose of the SBRT boost will be determined. SECONDARY OBJECTIVES: 1. To assess local control. 2. To assess distant metastasis and patterns of failure. 3. To assess overall survival at 1 and 2 years. OUTLINE: This is a dose-escalation study of radiation therapy and SBRT. Patients undergo radiation therapy daily and receive carboplatin and paclitaxel weekly for 4.5 weeks. Patients then undergo 2 boost SBRT treatments 2-3 days apart. After completion of study treatment, patients are followed up for 5 years.

Conditions

Interventions

TypeNameDescription
RADIATIONstereotactic body radiation therapyUndergo SBRT
DRUGcarboplatin
DRUGpaclitaxel
RADIATIONradiation therapyUndergo radiation therapy

Timeline

Start date
2012-09-04
Primary completion
2022-05-31
Completion
2022-05-31
First posted
2012-10-22
Last updated
2021-06-23

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01711697. Inclusion in this directory is not an endorsement.